An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Abstract: Restoring high-quality images from degraded hazy observations is a fundamental and essential task in the field of computer vision. While deep models have achieved significant success with ...
See Statistics Help for definitions of terms used.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results